NeuroSense Therapeutics Reports Positive Final Results from Alzheimer’s Biomarker Study

NeuroSense Therapeutics announced final results from a biomarker study conducted to evaluate the potential of NeuroSense’s combination platform therapy for the treatment of Alzheimer’s disease (AD). Preliminary results from the study, showed that TDP-43, a novel biomarker, was elevated in AD patients compared to a healthy control group. Based on these encouraging preliminary results, NeuroSense expanded the study with a larger healthy control group to further validate the results.

Share:

Join Our Newsletter

Skip to content